The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

The approval of immunotherapeutic agents and immunotherapy-based combination strategies in recent years has revolutionized the treatment of patients with advanced renal cell carcinoma (aRCC). Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor monoclonal antibody, was approved as mono...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Immunother Cancer
Main Authors: Rini, Brian I., Battle, Dena, Figlin, Robert A., George, Daniel J., Hammers, Hans, Hutson, Tom, Jonasch, Eric, Joseph, Richard W., McDermott, David F., Motzer, Robert J., Pal, Sumanta K., Pantuck, Allan J., Quinn, David I., Seery, Virginia, Voss, Martin H., Wood, Christopher G., Wood, Laura S., Atkins, Michael B.
格式: Artigo
語言:Inglês
出版: BioMed Central 2019
主題:
Position Article and Guidelines
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6924043/
https://ncbi.nlm.nih.gov/pubmed/31856918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0813-8
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍